H. Bacquet-Deschryver

Impact of Three Anti-TNFα Biologics on Existing and Emergent Autoimmunity in Rheumatoid Arthritis and Spondylarthropathy Patients

J. Ménard, O. Vittecoq, F. Tron, 2008, Journal of Clinical Immunology.

Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.

G. Savoye, J. Ménard, X. le Loët, 2009, Rheumatology.

A 3 mg/kg starting dose of infliximab in active spondyloarthritis resistant to conventional treatments is efficient, safe and lowers costs.

X. le Loët, O. Vittecoq, S. Pouplin, 2011, Joint, bone, spine : revue du rhumatisme.

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

Julie M. Woessner, P. Hennequin, Cécile Paris, 2021, The Lancet Rheumatology.